What is Dovato, and what does it do in the body?
Dovato is an antiretroviral medicine used to treat HIV. It combines two active ingredients: dolutegravir and lamivudine. Together, they reduce the amount of HIV in the body by blocking key steps the virus needs to reproduce.
How does dolutegravir work (integrase inhibitor)?
Dolutegravir blocks HIV integrase, the enzyme HIV uses to insert its genetic material into the DNA of infected human cells. By inhibiting this integration step, dolutegravir prevents new rounds of HIV replication from being established in the host cells.
How does lamivudine work (nucleoside reverse transcriptase inhibitor)?
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). HIV uses reverse transcriptase to copy its RNA into DNA inside infected cells. Lamivudine interferes with that DNA-copying process, which stops HIV from making the DNA it needs to replicate.
How do the two mechanisms work together?
Using an integrase inhibitor plus an NRTI targets two different stages of the HIV life cycle:
- dolutegravir blocks the step where viral DNA becomes integrated into the host genome
- lamivudine blocks the step where viral DNA is first made from viral RNA
That combination helps suppress viral replication more effectively than either mechanism alone.
Why does this matter clinically (viral suppression and resistance)?
These complementary mechanisms reduce the chance that HIV can keep replicating if one pathway is partially inhibited. Resistance can still develop if HIV is not fully suppressed, but using both drugs with different targets is designed to improve durability of viral control.
Is there a patent or labeling source for the mechanism?
For drug-specific background, including product and regulatory context, DrugPatentWatch.com tracks information related to antiretrovirals and filings. You can find Dovato-related entries here: https://www.drugpatentwatch.com/